JAMES C YAO to Gastrointestinal Neoplasms
This is a "connection" page, showing publications JAMES C YAO has written about Gastrointestinal Neoplasms.
Connection Strength
4.702
-
Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer. 2018 02 15; 124(4):807-815.
Score: 0.406
-
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 01; 3(10):1335-1342.
Score: 0.401
-
Everolimus in ileum neuroendocrine tumours - Authors' reply. Lancet. 2016 Jul 16; 388(10041):236-7.
Score: 0.369
-
Future Directions in the Biology of Neuroendocrine Tumors. Pancreas. 2016 07; 45(6):783-5.
Score: 0.368
-
[177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors. Future Oncol. 2016 Feb; 12(3):313-21.
Score: 0.356
-
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016 Mar 05; 387(10022):968-977.
Score: 0.354
-
Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials. J Clin Oncol. 2015 Sep 10; 33(26):2914-9.
Score: 0.346
-
A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors. Annu Rev Med. 2015; 66:1-16.
Score: 0.327
-
Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014 Sep 15; 120(18):2814-23.
Score: 0.316
-
Molecular pathology and genetics of gastrointestinal neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes. 2014 Feb; 21(1):22-7.
Score: 0.311
-
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008 Mar 10; 26(8):1316-23.
Score: 0.207
-
Markers of Systemic Inflammation in Neuroendocrine Tumors: A Pooled Analysis of the RADIANT-3 and RADIANT-4 Studies. Pancreas. 2021 02 01; 50(2):130-137.
Score: 0.126
-
Poorly-differentiated endocrine carcinomas of midgut and hindgut origin. Neuroendocrinology. 2008; 87(1):40-6.
Score: 0.101
-
Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 10; 18(10):1411-1422.
Score: 0.100
-
Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary. Neuroendocrinology. 2018; 106(3):211-220.
Score: 0.098
-
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 01 12; 376(2):125-135.
Score: 0.095
-
Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection. Surgery. 2017 03; 161(3):753-759.
Score: 0.094
-
Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis. Endocr Relat Cancer. 2015 Dec; 22(6):933-40.
Score: 0.087
-
Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology. 2011 Nov; 141(5):1728-37.
Score: 0.065
-
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010 Aug; 39(6):735-52.
Score: 0.061
-
Attempted salvage resection for recurrent gastric or gastroesophageal cancer. Ann Surg Oncol. 2009 Jan; 16(1):42-50.
Score: 0.054
-
New drug development in digestive neuroendocrine tumors. Ann Oncol. 2007 Aug; 18(8):1307-13.
Score: 0.048
-
Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors. Genes Chromosomes Cancer. 2008 Jan; 47(1):84-92.
Score: 0.013